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SUMMARY
NOD-like receptor (NLR) proteins are intracellular innate immune sensors/receptors that regulate 
immunity. This work shows that NLRX1 serves as a tumor suppressor in colitis-associated cancer 
(CAC) and sporadic colon cancer by keeping key tumor promoting pathways in check. Nlrx1−/− 
mice were highly susceptible to CAC, showing increases in key cancer-promoting pathways 
including nuclear factor κB (NF-κB), mitogen-activated protein kinase (MAPK), signal transducer 
and activator of transcription 3 (STAT3), and interleukin 6 (IL-6). The tumor-suppressive function 
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of NLRX1 originated primarily from the non-hematopoietic compartment. This prompted an 
analysis of NLRX1 function in the Apcmin/+ genetic model of sporadic gastrointestinal cancer. 
NLRX1 attenuated Apcmin/+ colon tumorigenesis, cellular proliferation, NF-κB, MAPK, STAT3 
activation, and IL-6 levels. Application of anti-interleukin 6 receptor (IL6R) antibody therapy 
reduced tumor burden, increased survival, and reduced STAT3 activation in Nlrx1−/−Apcmin/+ 
mice. As an important clinical correlate, human colon cancer samples expressed lower levels of 
NLRX1 than healthy controls in multiple patient cohorts. These data implicate anti-IL6R as a 
potential personalized therapy for colon cancers with reduced NLRX1.
Graphical Abstract
INTRODUCTION
Members of the nucleotide binding domain and leucine-rich repeat-containing (NLR, also 
known as NOD-like receptor) family are evolutionarily conserved components of the 
immune system that are key mediators of immune defense and inflammation (Takeuchi and 
Akira, 2010). The major focus in the NLR field is on the inflammasome NLRs, which 
activate caspase-1 resulting in production of interleukin 1β (IL-1β) and interleukin 18 
(IL-18). A subgroup of NLRs play an important role in the regulation of signaling pathways 
crucial for cell proliferation, survival, cellular differentiation, adhesion, migration, and 
metabolism, such as mitogen-activated protein kinases (MAPK) and nuclear factor κB (NF-
κB) (Hayden and Ghosh, 2011; Sebolt-Leopold and Herrera, 2004; Wullaert et al., 2011). 
Aberrant activation of these pathways initiate and promote tumor development (Elinav et al., 
2013); thus, it is important to determine if NLRs control these pathways during 
tumorigenesis and if these findings have translational relevance in human cancers.
Colorectal cancer (CRC) is the third most common cancer in both men and women and the 
second leading cause of cancer-related mortality in the United States with estimates of over 
130,000 new cases diagnosed and 50,000 deaths in 2013 (Siegel et al., 2013). Recent studies 
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reported an increased frequency of colon cancer in adults younger than 50, with these 
patients more likely to show an advance stage of the disease (Bailey et al., 2015). Over 90% 
of CRCs are adenocarcinomas, while rarer forms include neuroendocrine, squamous cell, 
spindle cell, and undifferentiated carcinomas (Fleming et al., 2012).
Colitis-associated colon cancer (CAC) accounts for 1% of CRC (Yashiro, 2014). The link 
between chronic inflammation and increased tumorigenesis has been well documented in 
inflammatory bowel diseases (IBD), including ulcerative colitis (UC), and Crohn's disease 
(CD) (Rogler, 2014; Terzić et al., 2010). IBD are associated with increased production of 
pro-inflammatory cytokines, which are associated with the activation of NF-κB, signal 
transducer and activator of transcription 3 (STAT3), and mitogen-activated protein kinase 
(MAPK). Each of these pathways contributes to tumor progression in CRC (Ben-Neriah and 
Karin, 2011; Dhillon et al., 2007; O'Shea et al., 2013). NF-κB regulation of CRC 
development occurs through the enhanced survival of pre-malignant epithelial cells and 
release of inflammatory cytokines, which promote tumor growth (Ditsworth and Zong, 
2004; Greten et al., 2004; Staudt, 2010). Elevated levels of IL-1β, tumor necrosis factor α 
(TNF-α), and interleukin 6 (IL-6) are commonly associated with both IBD and CRC (Becker 
et al., 2005; Lin and Karin, 2007; Waldner et al., 2012). In particular, IL-6 and STAT3 
potently stimulate colon cancer proliferation and have critical roles in colon tumor 
development in preclinical models (Bollrath et al., 2009; Corvinus et al., 2005; Grivennikov 
et al., 2009). There is also a strong correlation between local IL-6 accumulation and clinical 
activity of IBD in humans (Atreya and Neurath, 2005; Hyams et al., 1993).
The initial connection between IBD and the NLR family was based on the strong genetic 
association between NOD2/CARD15 mutations in Crohn's disease and colon cancer (Hugot 
et al., 2001; Kurzawski et al., 2004; Ogura et al., 2001). Mouse models of CAC have 
demonstrated that other NLRs, such as NLRP3, NLRP6, and NLRP12, also protect against 
CAC (Allen et al., 2010; Anand et al., 2012; Chen et al., 2011; Dupaul-Chicoine et al., 2010; 
Elinav et al., 2011; Zaki et al., 2010). The NLRP3 and NLRP6 inflammasomes appear to 
limit CAC primarily through the induction of IL-18, while NLRP12 reduces NF-κB and 
ERK activation, hence reducing chemokines and nitric oxide that promote tumorigenesis 
(Allen et al., 2012; Zaki et al., 2011).
NLRX1 does not exhibit inflammasome function and is uniquely localized to the 
mitochondria (Moore et al., 2008; Tattoli et al., 2008). NLRX1 attenuates TRAF6, 
mitochondrial antiviral signaling protein (MAVS)/retinoic acid-inducible gene I (RIG-I), 
interferon regulatory factor 3 (IRF3), and IκB kinase (IKK) signaling in response to viral 
infection and TLR signaling (Allen et al., 2011; Moore et al., 2008; Xia et al., 2011), but it is 
also required for the induction of reactive oxygen species in response to pathogens (Abdul-
Sater et al., 2010; Tattoli et al., 2008). As a result of its impact on key signaling pathways, 
NLRX1 negatively regulates the expression of pro-inflammatory cytokines, including IL-6 
(Allen et al., 2011), a cytokine that has a central role in CAC and is a target of therapies for 
the treatment of IBD (Allocca et al., 2013). A recent study reported that NLRX1 expression 
is reduced in patients with chronic obstructive pulmonary disease (COPD), and the absence 
of NLRX1 exacerbated a model of COPD (Kang et al., 2015). Thus, one of the functions of 
NLRX1 is to attenuate over-zealous immune responses. Therefore, elucidating the molecular 
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regulation and function of NLRX1 in CAC or sporadic CRC has the potential to identify 
novel pathways and therapeutic targets for the treatment of colon cancer.
Analyses of inflammasome NLRs in models of CAC have been well reported; however, 
CAC represents only 1% of CRC. By contrast, the importance of NLRs in the more 
prevalent sporadic colon tumors is sorely lacking. This current study identifies an important 
role for Nlrx1 in suppressing tumorigenesis in both CAC and sporadic colon cancer models 
by restricting the activation of NF-κB, MAPK, STAT3, and IL-6 production. In contrast to 
most inflammasome NLRs, which function through the myeloidmonocytic hematopoietic 
system, NLRX1 exerts its impact primarily through non-hematopoietic cells such as colon 
crypt cells. The importance of NLRX1 in cells other than hematopoietic is consistent with its 
role in sporadic CRC modeled after familial adenomatous polyposis (FAP). FAP is a 
hereditary disease characterized by the development of colon polyps, attributed to the 
deletion of the APC (adenomatous polyposis coli) gene (Fodde et al., 2001). Mutations in 
the APC gene also lead to sporadic colon cancer. The ApcMin/+ mouse model has a point 
mutation in the Apc gene, which predisposes the mice to increased spontaneous intestinal 
polyps. This study reveals that compared to Apcmin/+ controls, Apcmin/+ mice lacking Nlrx1 
have a dramatically increased tumor burden accompanied by increased IL-6, STAT3, β-
catenin, and cathepsin B activation. Treatment of Nlrx1−/−ApcMin/+ mice with anti-IL6R 
therapy reduced STAT3 activation, decreased tumor number, and increased survival, 
indicating that increased IL-6 is a causative factor in tumorigenesis linked to NLRX1-
deficiency. Expression analyses of clinical human colon cancer samples and meta-analysis 
of multiple public databases revealed that NLRX1 expression is significantly lowered in 
CRC when compared to normal colon tissues. These findings indicate that the loss or 
reduction of NLRX1 may contribute to human colon cancers.
RESULTS
Nlrx1−/− Mice Are More Susceptible to Chronic Azoxymethane/Dextran Sodium Sulfate-
Induced Colitis-Associated Colon Cancer
To test the hypothesis that NLRX1 impacts colon tumorigenesis, Nlrx1−/− and wild-type 
(WT) littermates were subjected to a well-characterized CAC model that combines the 
genotoxic DNA-methylation agent, azoxymethane (AOM), and dextran sodium sulfate 
(DSS) (Neufert et al., 2007). CAC was induced by injecting a single dose of AOM, followed 
by three cycles of 3% DSS administration for 5 days followed by 14 days of regular drinking 
water, hereafter referred to as A/D treatment (Figure 1A). A/D-treated Nlrx1−/− mice 
exhibited statistically greater weight loss than A/D-treated wild-type mice (Figure 1B). A 
clinical score based on body condition, stool consistency, rectal bleeding, and the presence 
of blood in the stool (Allen et al., 2010) was significantly higher in Nlrx1−/− animals 
compared to WT controls (Figure 1C). The histologic appearance of the Nlrx1−/− colons 
harvested at 55 days post A/D injection showed increased total histology score (THS) 
(Figures 1D and 1E), which evaluates severity and extent of inflammation, epithelial defects, 
crypt atrophy, and mucosal dysplasia/neoplasia. Nlrx1−/−-treated colons had more 
widespread epithelial defects compared to controls as scored in a blinded fashion by a 
board-certified veterinarian pathologist (Figure 1F, see legend for a detailed description).
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On day 55 after the start of A/D, colons were harvested and macroscopic polyps were 
counted. A/D-treated Nlrx1−/− mice exhibited significantly more polyps in the distal region 
of their colons compared to A/D-treated WT controls (Figure 1G). Nlrx1−/− mice also 
exhibited greater tumor volume compared to WT controls (Figure S1A). Mice treated with 
DSS or AOM alone had few, if any, polyps. Further analysis by endoscopy with a different 
group of mice revealed that A/D-treated Nlrx1−/− mice developed more polyps or lesions at 
the time of examination (day 48 of the A/D treatment course) compared to WT control mice 
(Figure S1B). NLRX1 attenuates cytokine expression in fibroblasts (Allen et al., 2011). To 
assess if this occurs in CAC, serum from A/D-treated Nlrx1−/− mice were prepared and 
showed significantly higher levels of IL-6, TNF-α, and IL-1β protein than controls as 
determined by ELISA (Figure 1H) and greater Il6, Tnfα, and Il1β RNA expression as 
determined by real-time PCR from colon tissues (Figure 1I). Previous reports have 
demonstrated the role of increased NF-κB and ERK activation in CAC development (Greten 
et al., 2004). Western blot analysis revealed that colons of chronic DSS- or A/D-treated 
Nlrx1−/− mice had higher levels of phosphorylated IκBα and ERK1/2 compared to WT 
controls (Figures 1J and 1K). Furthermore, IL-6 induces the activation of STAT3, which is 
dysregulated in colon cancer. Colons from A/D-treated Nlrx1−/− mice had significantly 
higher levels of phosphorylated STAT3 compared to WT controls (Figures 1J and 1K). 
These results show that NLRX1 mitigates several known tumor-promoting signaling 
pathways during CAC.
Nlrx1 Expression in the Non-hematopoietic Compartment Mediates Protection against 
Colon Tumorigenesis
NLRX1 is widely expressed in different tissues and organs (Moore et al., 2008), hence its 
impact on CAC might be attributed to its expression in hematopoietic and/or non-
hematopoietic cells. To address this, the following four groups of bone marrow chimeras 
were generated to test whether hematopoietic and/or non-hematopoietic cells were needed to 
protect against polyp formation: (1) irradiated WT mice that received bone marrow from 
WT littermates (WT > WT, control group), (2) irradiated WT control mice that received 
bone marrow from Nlrx1−/− donors (Nlrx1−/− > WT, hematopoietic component was Nlrx1-
deficient), (3) irradiated Nlrx1−/− mice that received bone marrow from Nlrx1−/− donors 
(Nlrx1−/− > Nlrx1−/−, global Nlrx1 deficiency), and (4) irradiated Nlrx1−/− mice that 
received bone marrow from WT donors (WT > Nlrx1−/−, non-hematopoietic compartment 
was Nlrx1-deficient). All reconstituted mice were treated with A/D and monitored for 55 
days. Within the first 10–15 days post A/D treatment, almost 50% of the Nlrx1−/− > Nlrx1−/− 
and WT > Nlrx1−/− mice died (Figure 2A). Of the mice that survived, a clinical score was 
assessed. WT > Nlrx1−/− and Nlrx1−/− > Nlrx1−/− groups showed increased clinical scores 
compared to the WT > WT controls and the Nlrx1−/− > WT groups at all three indicated 
time points (Figure 2B). WT > Nlrx1−/− and Nlrx1−/− > Nlrx1−/− groups had an increase in 
THS when compare to Nlrx1−/− > WT group and WT > WT controls (Figures 2C and 2D). 
Nlrx1−/− > Nlrx1−/− had a higher THS possibly due to the fact that NRLX1 is expressed in 
many different cell types (Figure 2D). Similar to findings with non-chimeric Nlrx1−/− mice, 
the Nlrx1−/− > Nlrx1−/− group had a higher number of colonic polyps than WT > WT 
controls (Figure 2E). WT > Nlrx1−/− mice showed significantly higher numbers of polyps 
than the WT > WT and Nlrx1−/− > WT mice (Figure 2E). Colonic polyp numbers in 
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Nlrx1−/− > WT mice were not significantly different from WT > WT controls. Nlrx1−/− > 
Nlrx1−/− and WT > Nlrx1−/− mice, but not Nlrx1−/− > WT mice, had significantly increased 
tumor volume compared to WT > WT mice (Figure 2F). Additionally, phosphorylated 
STAT3 was higher in Nlrx1−/− > Nlrx1−/− and WT > Nlrx1−/− mice compared to Nlrx1−/− > 
WT and WT > WT mice (Figure 2G). A composite of three experiments confirmed these 
results (Figure 2H). These results indicate that the presence of Nlrx1 in the non-
hematopoietic compartment is primarily required to limit A/D-induced tumorigenesis and 
STAT3 activation.
Loss of Nlrx1 in the Apcmin/+ Model of Sporadic CRC Leads to Increased Mortality and 
Tumor Burden
The above data indicate a contribution of Nlrx1-deficiency from the non-hematopoietic 
compartment during CAC pathogenesis. However, the majority of colon cancers are not 
associated with CAC. Therefore, we explored the role of NLRX1 in a model of sporadic 
colon cancer. APC mutations are found in ~85% of human colon cancers or precancerous 
adenomas, and the loss of APC in epithelial cells is sufficient to drive intestinal 
tumorigenesis (Kinzler and Vogelstein, 1996; Schwitalla et al., 2013). Apcmin/+ mice have a 
germline mutation in the APC gene and develop spontaneous polyps (Fodde et al., 2001). 
Usually, Apcmin/+ mice become moribund within 168 days of age due to complications from 
intestinal tumors (Heyer et al., 1999). To explore the role of NLRX1 in a model of sporadic 
colon cancer, Nlrx1−/− mice were bred with Apcmin/+ mice to test if the loss of Nlrx1 
affected spontaneous tumor development and lethality. Survival of Nlrx1−/−Apcmin/+ mice 
was dramatically decreased when compared to Apcmin/+ littermate controls (Figure 3A). 
Mice were monitored and harvested at 42, 84, and 168 days of age to elucidate potential 
factors of early mortality (Figure S2A). At 168 days, Nlrx1−/−Apcmin/+ mice exhibited 
obvious signs of hunched back (Figure S2B), which correlated with an increase in clinical 
score (Figure 3B). Apcmin/+ and Nlrx1−/−Apcmin/+ mice did not differ in body weight at 84 
to 168 days, although there was a slight and statistically significant difference between 
Nlrx1−/− and WT mice at 42 days (Figure S2C). Macroscopic analysis of unstained colons 
and colons stained by Alcian blue revealed that Nlrx1−/−Apcmin/+ colons had increased 
polyps (Figure 3C). The numbers of visible polyps were quantified at three different time 
points. At 42 days of age, colonic (Figure 3D) polyp numbers were not significantly 
different among the four groups. However, at 84 days and 168 days of age, a modest number 
of polyps appeared in Apcmin/+ mice as reported in the literature (Heyer et al., 1999), while 
Nlrx1−/−Apcmin/+ mice developed significantly more visible polyps in their colons compared 
to Apcmin/+ mice (Figure 3D). In addition, Nlrx1−/−Apcmin/+ colons had larger tumor volume 
when compared to Apcmin/+ colons (Figure 3E). These results suggest that NLRX1 
attenuates both polyp number and tumor volume during sporadic colon cancer.
NLRX1 Attenuates Aberrant Cellular Proliferation and Disease Progression in the APCmin/+ 
Mouse Tumor Model
Histological analysis of H&E-stained colons from 168-day-old Nlrx1−/−Apcmin/+ mice 
revealed a higher THS marked by more severe histologic lesions, including increased 
incidence of colonic dysplasia and neoplasm compared to similar-aged Apcmin/+ or Nlrx1−/− 
mice (Figure 4A, see figure legend for a detailed description of the histology). We also 
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observed a higher rate of distal inflammation in the colons of Nlrx1−/−Apcmin/+ mice (Figure 
4B). In addition, we observed no difference in the percentage of cleaved caspase 3, a marker 
of apoptosis, between WT and Nlrx1−/− (Figure 4C) while we saw significantly higher levels 
of Ki67+ cells in the basal end of colon crypts in Nlrx1−/− and Nlrx1−/−Apcmin/+ mice 
compared to wild-type and Apcmin/+ mice, which is an indicator of increased proliferation 
(Figures 4D and 4E). APC controls the stability of β-catenin, a key regulator of Wnt 
signaling, stem cell renewal, cell fate, and growth (Clevers and Nusse, 2012). Additionally, 
increased cytoplasmic β-catenin is a marker of carcinogenesis (Fodde et al., 2001). 
Immunohistochemical staining of Nlrx1−/−Apcmin/+ tumors showed increased β-catenin 
compared to Apcmin/+ controls (Figure 4F).
Our findings indicate that STAT3 was hyperactivated in the absence of NLRX1 (Figure 1J). 
STAT3 is known to activate cathepsin-B, which is involved in the oncogenesis and 
metastasis of human cancers and it is upregulated in dysplastic adenomas and colorectal 
carcinoma (Ding et al., 2014; Kuester et al., 2008). Ex vivo imaging of colons of 
Nlrx1−/−Apcmin/+ mice, Apcmin/+, Nlrx1−/−, and WT controls injected with a cathepsin B-
inducible fluorescence probe (Prosense 680) (Ding et al., 2014; Gounaris et al., 2013) 
revealed significantly higher fluorescence in colons of Nlrx1−/−Apcmin/+ versus Apcmin/+ 
mice, which is indicative of increased cathepsin B activity in the Nlrx1−/−Apcmin/+ mice 
(Figure 4G). Colons of Nlrx1−/− and WT littermates showed minimal cathepsin B signals 
(Figure 4G). This result indicates that cathepsin B activity is enhanced in Nlrx1−/−Apcmin/+ 
mice.
NLRX1 Attenuates Tumor-Promoting Signaling Pathways in Colon Crypts during the 
Apcmin/+ Model of Spontaneous CRC
To assess whether the presence of NLRX1 attenuated key tumor-promoting pathways in the 
Apcmin/+ model, colons were isolated and analyzed by western blot. Nlrx1−/−Apcmin/+ 
colons had higher levels of phosphorylated p65, IκBα, JNK1/2, and ERK1/2 at 84 (Figure 
5A) and 168 (Figure 5B) days of age compared to Nlrx1−/−, Apcmin/+, and WT mice. 
Phosphorylated STAT3 was also elevated in Nlrx1−/−Apcmin/+ colons (Figures 5A and 5B). 
Since Nlrx1−/−Apcmin/+ had increased levels of Ki67+ in their colon crypt (Figure 4D), we 
isolated these cells to determine the impact of NLRX1-deficiency. These cells were 
EpCAMhi and CD45lo (Figure S3). Nlrx1−/−Apcmin/+ colon crypts from 84-day-old mice 
had higher levels of phosphorylated p65, ERK1/2, and STAT3 (Figure 5C) than controls. 
Since STAT3 can be activated by the key tumor-promoting cytokine, IL-6, Il6 transcript was 
measured by qPCR, and it was significantly increased in Nlrx1−/−Apcmin/+ colons (Figure 
5D). In contrast, levels of Tnfα and Il1β were not significantly different between Apcmin/+ 
and Nlrx1−/−Apcmin/+ colons (Figure 5D). ELISA analysis verified significantly higher 
levels of IL-6 protein produced by colonic samples isolated from Nlrx1−/−Apcmin/+ animals 
compared to Apcmin/+ mice, but no difference in IL-1β and TNF-α, which was below 
detection (Figure 5E). Taken together, these results indicate that the loss of NLRX1-
activated multiple pathways that contribute to tumor development or progression.
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Anti-IL6R Therapy Significantly Decreases Tumor Burden and STAT3 Activity in the Nlrx1−/
−Apcmin/+ Animals
To assess whether the pathways delineated above contributed to the mechanism by which 
NLRX1 suppressed tumor growth, we directly assessed the role of elevated IL-6 in 
Nlrx1−/−Apcmin/+ animals with antibodies against IL-6 receptor. WT, Nlrx1−/−, Apcmin/+, 
and Nlrx1−/−Apcmin/+ animals were injected with 20 μg/ml of anti-IL6R per mouse biweekly 
for 10 weeks. Cumulative clinical score revealed that Nlrx1−/−Apcmin/+ mice on anti-IL6R 
treatment had a significantly lowered clinical score compared to the untreated (UT) 
Nlrx1−/−Apcmin/+ group (Figure 6A). Anti-IL6R-treated Nlrx1−/−Apcmin/+ mice showed 
significant weight gain compared to UT controls, while anti-IL6R-treated WT, Nlrx1−/−, and 
Apcmin/+ showed a modest, but insignificant weight loss compared to their UT controls 
(Figure 6B). After 10 weeks of anti-IL-6R therapy, colons were harvested and macroscopic 
polyps were counted. Anti-IL6R-treated Nlrx1−/−Apcmin/+ animals exhibited significantly 
less polyps in the distal region of their colons in comparison to UT Nlrx1−/−Apcmin/+ 
(Figures 6C and 6D). Western blot showed a significant decrease of phosphorylated STAT3 
in anti-IL6R-treated Nlrx1−/−Apcmin/+ animals in comparison to UT animals (Figure 6E). 
STAT3 is well documented to regulate the initial events of tumor development, progression, 
and invasiveness (Waldner et al., 2012) (Figure 6F) and decreased levels of phosphorylated 
STAT3 observed in anti-IL6R-treated Nlrx1−/−Apcmin/+ animals correlated positively with 
decreased polyp numbers (Figures 6D and 6F). Thus, these results indicate that increased 
IL-6 found in Nlrx1−/−Apcmin/+ played a causative role in increased polyp formation and 
heightened STAT3 activation.
NLRX1 Expression Is Reduced in Colorectal Cancer Based on Analysis of the Oncomine 
Platform and Newly Isolated Clinical Samples
To examine the relevance of the data in preclinical models to human colon cancer, the levels 
of NLRX1 expression in human CRC was subjected to bioinformatics mining using the 
Oncomine Platform database. This was followed by an examination of newly isolated 
clinical samples from a Chinese Cohort. Oncomine Platform is an online assembly of 
microarrays. We analyzed five databases (listed in the Experimental Procedures) that 
contained information regarding NLRX1 expression. We first analyzed the Cancer Genome 
Atlas (TCGA) database, which is the most comprehensive set containing 215 patient and 22 
control samples (Cancer Genome Atlas, 2012). This database showed that the expression of 
NLRX1 transcript was significantly decreased in colorectal cancer (Figure 7A). Next, we 
evaluated the expression levels of NLRX1 transcript at various stages of cancer progression 
using the TCGA database (Figure 7B). CRC cases were staged according to the staging 
system determined by the American Joint Committee on Cancer (AJCC) and also known as 
the tumor-node-metastasis (TNM) system. In stage I, the tumor has spread beyond the inner 
lining of the colon to the second and third layers of the colon. In stage II, the tumor has 
spread to the muscle wall of the colon. In stage III, the cancer has metastasized to lymph 
nodes. In stage IV, the cancer has metastasized to secondary areas of the body such as the 
liver or lung. This analysis shows that NLRX1 expression was significantly higher in healthy 
controls versus all four CRC stages (Figure 7B). Next, we confirmed these findings using 
four smaller databases within the Oncomine Platform. Significantly lower expression of 
NLRX1 was detected in CRC samples in all four databases (Figure 7C). Thus, the composite 
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data from five public databases support the conclusion that NLRX1 expression is statistically 
lower in CRC than in healthy colons.
Public database typically do not provide detailed information regarding the patients. Thus, 
we analyzed mRNA isolated from 40 formalin-fixed and paraffin-embedded (FFPE) CRC 
samples plus 40 adjacent normal tissues obtained from a Chinese patient cohort for the 
expression of NLRX1. The patients selected had not received any chemotherapy or 
radiotherapy prior to colonic resection. In agreement with Figure 7A, NLRX1 transcripts 
were significantly reduced within the CRC samples relative to healthy tissues (Figure 7D). 
The combined data collected from multiple public databases and an additional cohort of 
human clinical samples provides overwhelming clinical evidence that NLRX1 gene 
expression is reduced in human CRC in comparison to healthy colons, further indicating a 
critical role for NLRX1 in limiting CRC.
DISCUSSION
The link between cancer and a number of key signaling pathways is well established 
(Coussens and Werb, 2002). Elevated NF-κB signaling can de-differentiate intestinal 
epithelial cells that eventually acquire stem-like properties and tumor-initiating capacity 
(Shaked et al., 2012). NF-κB also facilitates Wnt-driven proliferation of intestinal stem cells, 
which leads to CRC (Myant et al., 2013; Schwitalla et al., 2013). MAPK regulates intestinal 
cell proliferation and epithelial differentiation and promotes progression and oncogenesis of 
human CRC (Dhillon et al., 2007; Lee et al., 2010; Taupin and Podolsky, 1999). NF-κB and 
STAT3 cooperatively regulate a number of target genes regulating cell cycle and 
proliferation (Lee et al., 2009; Yang et al., 2007). This work shows that NLRX1 serves as a 
checkpoint of these multiple critical cancer-promoting pathways to maintain a homeostatic, 
noncancerous state.
A previous study of NLRX1 in a model that used AOM alone, which is not known to 
strongly induce tumorigenesis, and a model that involved a short course (3-day) of AOM-
DSS treatment, which is unlikely to induce full tumorigenesis, has resulted in conflicting 
findings regarding the role of NLRX1 (Soares et al., 2014). In contrast, the current study is 
distinguished by several unique features First, NLRX1 uniformly suppressed colon tumor-
igenesis in both CAC and sporadic colon cancer models. Second, the loss of Nlrx1 
expression led to heightened IL-6 production and activated STAT3, which are key regulatory 
pathways in colon cancer that have not been connected to NLR function in tumors. 
Enhanced NF-κB and ERK activity are known to enhance levels of IL-6, which can lead to 
STAT3 activation resulting in increased oncogenesis (Corvinus et al., 2005). Cross talk 
between STAT3 and β-catenin have been documented in different cancers (Armanious et al., 
2010; Ibrahem et al., 2014), and STAT3 can also enhance cathepsin B (Dauer et al., 2005), 
which enhances cancer progression and cell proliferation. Since cathepsin B and β-catenin 
activity are heightened in Nlrx1−/−Apcmin/+ mice, inhibitors of these two proteins may be 
useful in targeting human CRCs with low NLRX1 expression. Third, while other NLRs such 
as NLRP3 exert their impact primarily through the hematopoietic compartment, NLRX1 
exerts its impact on tumorigenesis mostly via the non-hematopoietic compartment such as 
colon crypts. Fourth, anti-IL6R therapy effectively decreased tumorigenesis and STAT3 
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activation in Nlrx1−/−Apcmin/+ animals. Finally, NLRX1 is also reduced in multiple human 
CRC patient cohorts, which confers translational relevance to these findings and supports the 
concept that NLRX1 may serve as a checkpoint against human colon cancer. The discovery 
of reduced NLRX1 in human CRC further suggests that NLRX1 expression may be used as 
a biomarker of CAC or CRC (Thorsteinsdottir et al., 2011). This finding also has 
implications for personalized therapy. For example, inhibitors of STAT3 or IL-6, which are 
Food and Drug Administration (FDA)-approved for other diseases, might be repurposed for 
controlling human CRCs that have low NLRX1 expression. Based on the findings in this and 
previous reports, a working model of how NLRX1 affects tumorigenesis is shown in Figure 
6F.
In summary, this report finds that the presence of NLRX1 limits activation of key signaling 
pathways leading to NF-κB, MAPK, IL-6, and STAT3 activation, which promote various 
aspects of tumor development. The loss of NLRX1 creates a microenvironment that 
potentiates the development of tumors in both colitis-associated and sporadic models of 
CRC. A possible impact is that NLRX1 affects tumor-promoting signals via changes in the 
microbiome, which would be an important future investigation.
EXPERIMENTAL PROCEDURES
Animals
All studies were conducted in accordance with IACUC guidelines of the University of North 
Carolina (UNC) at Chapel Hill and NIH guide for the Care and Use of Laboratory Animals. 
All experiments were performed under SPF conditions using either 6- or 8-week-old male 
mice or with age as indicated. C57BL/6 (wild-type mice) and Apcmin/+ mice originated from 
Jackson Laboratories and were maintained at UNC Chapel Hill for more than nine 
generations. Nlrx1−/− mice on the C57BL/6 background have been described previously 
(Moore et al., 2008). Nlrx1−/− mice were crossed with Apcmin/+ mice to generate 
Nlrx1−/−Apcmin/+ mice. Littermates were used as indicated. See the Supplemental 
Experimental Procedures for colitis and colon cancer models, generation of radiation bone 
marrow chimeras, and assessment of colon polyps and histopathology.
Assays
Isolation of RNA, tissue extracts, and soluble protein and biochemical and molecular 
analyses and molecular imaging of proteases are described in the Supplemental 
Experimental Procedures.
Bioinformatics and Experimental Analysis of NLRX1 Expression in Human CRC
Microarray studies from the Oncomine Platform containing data describing NLRX1 
expression in CRC and the collection and processing of human CRC specimens are 
described in the Supplemental Experimental Procedures.
Statistics
All results are presented as the mean ± SEM. Significance between two groups was assessed 
by the Studenty two-tailed t test. Datasets that had more than two sets of data for analysis 
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were analyzed by ANOVA with Tukey–Kramer HSD post test for multiple comparisons to 
determine significance. The product limit method of Kaplan-Meier was utilized for 
generating the survival curves, which were compared using the log rank test. See the 
Supplemental Experimental Procedures for statistics used with clinical human samples.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• NLRX1 mitigates tumorigenesis in a genetic model of sporadic colon cancer, 
APCmin/+
• Nlrx1−/− colons have increased activation of tumor inducing STAT3, NFκB, 
MAPK, and IL6
• Anti-IL6R therapy reduces mortality and tumor development in Nlrx1−/− 
APCmin/+ mice
• Human colon tumors exhibit significantly lower levels of NLRX1 in multiple 
datasets
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Figure 1. Nlrx1 Deficiency Leads to Increased Inflammation and Colitis-Associated 
Tumorigenesis
(A) In the chronic CAC model, WT and Nlrx1−/− mice were challenged with A/D.
(B) The percent weight change after A/D treatment is shown. Each data point is the average 
from three independent experiments with n indicated.
(C) Cumulative clinical scores were measured at days 7, 26, and 45. Each data point 
represents one animal.
(D) Photomicrographs show H&E-stained colons from untreated (UT) WT, UT Nlrx1−/−, 
A/D-treated WT with mild inflammation (black arrowhead) and crypt shortening (white 
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arrowhead), and A/D-treated Nlrx1−/− with extensive inflammation (black arrowhead), crypt 
loss and atrophy (white arrowhead) and early mucosal dysplasia (orange arrowhead). Scale 
bars represent 50 μm.
(E) Total histology score for UT or A/D-treated WT and Nlrx1−/− mice scored in a blinded 
fashion.
(F) Average epithelial defects were measured from H&E stained colons as indicated. Graph 
is a compilation of three separate experiments.
(G) Quantification of macroscopic polyp formation in the colons of WT and Nlrx1−/− mice 
after A/D treatment. Each data point represents one animal. Graph is a compilation of three 
separate experiments.
(H) Serum cytokine levels of IL-6, TNF-α, and IL-1β were measured by ELISA. Values are 
averages from two independent experiments. n ≥ 6 mice/group.
(I) Expression of Il6, Tnfα, and Il1β transcript in colon homogenates was measured by 
qPCR using comparative CT method (2−ΔΔCT) and graphed as fold over UT WT sample 
(mean ± SEM).
(J) Proteins isolated from distal colonic tissue obtained from UT or A/D-treated WT and 
Nlrx1−/− mice were analyzed for NF-κB, MAPK, and STAT3 activity by western blot 
analysis with indicated protein loading control. Each lane represents one animal.
(K) Densitometric measurement of western blots was obtained from three independent 
experiments. n ≥ 5 mice/group, n.s., non-significant. *p < 0.05, **p < 0.01, ***p < 0.001, 
and ****p < 0.0001.
See also Figure S1.
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Figure 2. Nlrx1 Expression in the Non-hematopoietic Compartment Is Primarily Required for 
Protection against AOM/DSS-Induced Tumorigenesis
Bone-marrow chimeras of WT and Nlrx1−/− mice were challenged with AOM and 2.5% 
DSS (A/D).
(A and B) Mice from two independent experiments were monitored for (A) mortality and 
(B) clinical score of disease; n ≥ 6 mice/group.
(C) Photomicrographs of H&E-stained colons from A/D-treated WT > WT with mucosal 
and submucosal inflammation (black arrowheads) and crypt shortening (white arrowhead); 
A/D-treated Nlrx1−/− > WT mice with similar features; A/D-treated Nlrx1−/− > Nlrx1−/− 
mice with extensive inflammation separating crypts (black arrowhead), crypt dysplasia 
(orange arrowhead), and partial penetration of muscularis mucosa (green arrowheads); A/D-
treated WT > Nlrx1−/− mice with inflammation (black arrowhead) and a sessile adenoma 
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(bracket) with dysplasia, including crypt infolding and branching and loss of goblet cells and 
nuclear polarization (orange arrowheads). Scale bars represent 50 μm.
(D) Total histology score of colons represented in (C).
(E) Macroscopic colonic polyps were counted on day 55 post-A/D treatment. Each data 
point represents one animal. Graph is the compilation of two independent experiments.
(F) Average colon tumor volume was measured. n ≥ 6 mice/group.
(G) Proteins isolated from distal portion of colons were analyzed by western blot for STAT3 
activation. Each lane represents one animal.
(H) Densitometric measurement of western blots was obtained from three independent 
experiments. n ≥ 5 mice/group, n.s., non-significant. *p < 0.05, **p < 0.01, ***p < 0.001, 
and ****p < 0.0001.
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Figure 3. Nlrx1 Deficiency Leads to Increased Disease and Polyp Burden in the Apcmin/+ Model 
and Sporadic CRC
(A) WT, Nlrx1−/−, Apcmin/+, and Nlrx1−/−Apcmin/+ mice were followed for 168 days for 
long-term survival; n ≥ 9 mice/group.
(B) Cumulative clinical score of WT, Nlrx1−/−, Apcmin/+, and Nlrx1−/−Apcmin/+ mice at 42, 
84, and 168 days Images of WT, Nlrx1−/−, Apcmin/+, and Nlrx1−/−Apcmin/+ mice at 84 and 
168 days of age.
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(C) Polyps in representative colons from mice at 84 (left) and 168 days (right) of age that 
were either unstained (top) or stained with Alcian blue. Polyps are highlighted by red 
circles.
(D and E) Quantification of macroscopic polyp formation and average tumor volume in the 
colons of WT, Nlrx1−/−, Apcmin/+, and Nlrx1−/−Apcmin/+ mice at 42, 84, and 168 days of 
age. Each data point represents one animal. n ≥ 5 mice/group, n.s., non-significant. *p < 
0.05, **p < 0.01, and ****p < 0.0001.
See also Figure S2.
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Figure 4. Nlrx1 Deficiency on the Apcmin/+ Background Leads to Increased Proliferation and 
Greater Expression of the Tumor Biomarkers β-Catenin and Cathepsin B
(A) Photomicrographs of H&E-stained colons from WT, Nlrx1−/−, Apcmin/+ mice displayed 
a pedunculated adenoma (bracket) with mucosal dysplasia, and Nlrx1−/−Apcmin/+ colons 
depicted an area of mucosal dysplasia within an adenoma. Scale bars represent 50 μm.
(B) Total Histology score and distal colon inflammation were determined in H&E-stained 
colon sections represented in A. All slides were scored in a blinded fashion.
(C–E) Quantification of positive cleaved caspase-3 (C) or Ki-67 (D) cells stained per half-
length of crypt was determined from age-matched Apcmin/+ and Nlrx1−/−Apcmin/+ mice at 
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168 days of age shown in (E) for Ki-67. n ≥ 4 mice/group, n.s., non-significant. *p < 0.05 
**p < 0.01, ***p < 0.001, and ****p < 0.0001. Scale bars represent 100 μm.
(F) Representative histological micrographs of Apcmin/+ and Nlrx1−/−Apcmin/+ colon tumors 
at 168 days stained with β-catenin are shown (arrows), n ≥ 3 mice/group. Scale bars 
represent 50 μm.
(G) Representative images of colons from WT, Nlrx1−/−, Apcmin/+, and Nlrx1−/−Apcmin/+ 
mice at 168 days of age are shown. Fluorescent signals (with intensity scale shown to right) 
due to active cathepsin B cleavage of target probe were visualized by fluorescence 
reflectance imaging. n ≥ 2 mice/group.
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Figure 5. Nlrx1 Deficiency Contributes to Exacerbated NF-κB, MAPK, and STAT3 Activation 
and IL-6 Production in the Apcmin/+ Model
(A–C) Protein lysates were isolated from distal colon tissues obtained from WT, Nlrx1−/−, 
Apcmin/+, and Nlrx1−/−Apcmin/+ mice at days 84 (A) and 168 (B), and isolated colon crypts 
from 84 days (C). Lysates were analyzed by western blot for NF-κB, MAPK, and STAT3 
activation. Each lane represents one animal; n ≥ 3 mice/group.
(D) RNA was isolated from age-matched WT, Nlrx1−/−, Apcmin/+, and Nlrx1−/−Apcmin/+ 
distal colonic tissues and analyzed by qPCR for expression levels of Il6, Tnfa, and Ilb, n ≥ 3 
mice/group.
(E) IL-6, TNF-α, and IL-1β proteins produced by colon explants were analyzed by ELISA, n 
≥ 3 mice/group. n.s., non-significant. *p < 0.05, ***p < 0.001, and ****p < 0.0001.
See also Figure S3.
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Figure 6. Inhibition of IL-6 Signaling in Nlrx1−/−Apcmin/+ Mice Reduces Mortality and 
Tumorigenesis by Decreasing STAT3 Activation
(A) WT, Nlrx1−/−, Apcmin/+, and Nlrx1−/−Apcmin/+ animals were subjected to anti-IL6R 
administration at 20 μg/ml/animal. Cumulative clinical score of animals on and off treatment 
were monitored.
(B) The percent weight change for animals that were untreated (UT) or given 10 weeks of 
anti-IL6R therapy is shown for each strain. n ≥ 4 mice/group.
(C) Images are shown of colons isolated at 10 weeks after anti-IL6R therapy from WT, 
Nlrx1−/−, Apcmin/+, and Nlrx1−/−Apcmin/+ animals with polyps indicated (arrows).
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(D) Quantification of macroscopic polyp formation in the colons of UT or anti-IL6R-treated 
animals as indicated. Each data point represents one animal. n ≥ 4 mice/group, n.s., non-
significant. *p < 0.05 **p < 0.01, ***p < 0.001, and ****p < 0.0001.
(E) Protein lysates were isolated from distal colon tissues obtained from WT, Nlrx1−/−, 
Apcmin/+, and Nlrx1−/−Apcmin/+ mice that were either left UT or were treated with anti-IL6R 
for 10 weeks. Lysates were analyzed by western blot for phosphorylated STAT3. Each band 
represents one animal; n ≥ 3 mice/group.
(F) Model of NLRX1 negatively impacting NF-κB and MAPK, which increase IL-6 to 
activate STAT3 and the downstream oncogenic cathepsin B and β-catenin pathways to 
increase proliferation in tumors.
Koblansky et al. Page 26
Cell Rep. Author manuscript; available in PMC 2016 May 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 7. NLRX1 Expression Is Reduced in Multiple Colorectal Cancer Patient Databases and in 
Clinical Samples
(A) CRC microarray databases were mined for NLRX1 expression. The raw data were 
exported from the TCGA CRC database, with representations of 22 healthy control and 215 
CRC samples. Mean ± SEM, presented as Log2 median-centered ratio expression. Unpaired 
Mann-Whitney test was used to evaluate the statistical significance.
(B) Correlation analysis compared expression levels of NLRX1 among different stages of 
CRC progression. TNM stage information was exported from the TCGA colon database.
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(C) Reduced NLRX1 expression was found in four additional CRC databases. Log2 median-
centered ratio expression is presented for the four datasets used. Box plots were generated 
by GraphPad, whiskers are drawn down to the 10th percentile and up to the 90th percentile. 
Points below and above the whiskers are drawn as individual dots.
(D) NLRX1 expression in human clinical CRC FFPE samples collected from a Chinese 
patient cohort (n = 40) was analyzed by qPCR using comparative CT method (2−ΔΔCT) 
(mean ± SEM). **p < 0.01, ***p < 0.001, and ****p < 0.0001.
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